VolitionRx Limited (VNRX) 10-Q 7 Nov 18 2018 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Sep. 30, 2018	Nov. 02, 2018
Document And Entity Information
Entity Registrant Name	VOLITIONRX LTD
Entity Central Index Key	93,314
Document Type	10-Q
Document Period End Date	Sep. 30, 2018
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Current Reporting Status	Yes
Entity Filer Category	Non-accelerated Filer
Entity Common Stock, Shares Outstanding		35,335,378
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2,018
Emerging Growth Company	false
Entity Small Business	true

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($)	Sep. 30, 2018	Dec. 31, 2017
Current Assets
Cash and cash equivalents	$ 16,374,428	$ 10,116,263
Prepaid expenses	460,124	248,661
Other current assets	229,780	202,295
Total Current Assets	17,064,332	10,567,219
Property and equipment, net	3,157,140	3,480,782
Intangible assets, net	494,422	576,397
Total Assets	20,715,894	14,624,398
Current Liabilities
Accounts payable	857,121	351,735
Accrued liabilities	1,244,636	1,278,428
Management and directors' fees payable	57,411	35,397
Current portion of long-term debt	337,156	443,908
Current portion of capital lease liabilities	137,383	139,084
Current portion of grants repayable	40,637	41,930
Total Current Liabilities	2,674,344	2,290,482
Long-term debt, net of current portion	1,871,361	1,312,785
Capital lease liabilities, net of current portion	744,322	874,684
Grants repayable, net of current portion	317,731	188,579
Total Liabilities	5,607,758	4,666,530
Commitments and Contingencies
STOCKHOLDERS' EQUITY
Common Stock Authorized: 100,000,000 shares of common stock, at $0.001 par value Issued and outstanding: 35,031,225 shares and 26,519,394 shares, respectively	35,031	26,519
Additional paid-in capital	84,444,318	65,774,870
Accumulated other comprehensive income (loss)	64,111	(129,343)
Accumulated deficit	(69,435,324)	(55,714,178)
Total Stockholders' Equity	15,108,136	9,957,868
Total Liabilities and Stockholders' Equity	$ 20,715,894	$ 14,624,398

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Sep. 30, 2018	Dec. 31, 2017
STOCKHOLDERS' EQUITY
Common Stock, par value	$ 0.001	$ 0.001
Common Stock, shares authorized	100,000,000	100,000,000
Common Stock, shares issued	35,031,225	26,519,394
Common Stock, shares outstanding	35,031,225	26,519,394

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Consolidated Statements Of Operations And Comprehensive Loss
Revenue
Operating Expenses
Research and development	2,737,856	2,133,470	7,847,531	5,619,085
General and administrative	1,450,383	1,555,770	4,949,716	4,374,736
Sales and marketing	259,302	185,795	845,253	662,245
Total Operating Expenses	4,447,541	3,875,035	13,642,500	10,656,066
Operating Loss	(4,447,541)	(3,875,035)	(13,642,500)	(10,656,066)
Other Expense
Interest expense	29,108	17,619	78,646	50,259
Net Loss	(4,476,649)	(3,892,654)	(13,721,146)	(10,706,325)
Other Comprehensive Income (Loss)
Foreign currency translation adjustments	46,350	(32,399)	193,454	60,415
Net Comprehensive Loss	$ (4,430,299)	$ (3,925,053)	$ (13,527,692)	$ (10,645,910)
Net Loss per Share - Basic and Diluted	$ (0.14)	$ (0.15)	$ (0.46)	$ (0.41)
Weighted Average Shares Outstanding - Basic and Diluted	32,826,924	26,512,195	30,071,635	26,343,101

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017
Operating Activities
Net Loss	$ (13,721,146)	$ (10,706,325)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	474,536	371,362
Loss on disposal of property and equipment	1,766	11,262
Stock based compensation	1,875,507	1,827,604
Warrants issued for services	6,453	38,806
Changes in operating assets and liabilities:
Deferred grant income		(50,855)
Prepaid expenses	(204,673)	(75,723)
Other current assets	202,290	12,749
Accounts payable and accrued liabilities	261,383	264,266
Net Cash Used In Operating Activities	(11,103,884)	(8,306,854)
Investing Activities:
Purchases of property and equipment	(183,541)	(1,340,230)
Net Cash Used in Investing Activities	(183,541)	(1,340,230)
Financing Activities:
Net proceeds from issuance of common shares	16,796,000	998,412
Proceeds from grants repayable	177,079
Proceeds from long-term debt	875,418	908,075
Payments from long-term debt	(369,915)	(29,807)
Payments on grants repayable	(40,864)	(38,487)
Payments on capital lease obligations	(103,999)	(94,227)
Net Cash Provided By Financing Activities	17,333,719	1,743,966
Effect of foreign exchange on cash	211,871	65,314
Net Change in Cash	6,258,165	(7,837,804)
Cash and cash equivalents - Beginning of Period	10,116,263	21,678,734
Cash and cash equivalents - End of Period	16,374,428	13,840,930
Supplemental Disclosures of Cash Flow Information:
Interest paid	78,845	50,234
Income tax paid
Non-Cash Financing Activities:
Common Stock issued on cashless exercises of stock options	12
Offering costs from stock issuances	$ 604,000

Nature of Operations

Nature of Operations	9 Months Ended
	Sep. 30, 2018
Notes to Financial Statements
Note 1 - Nature of Operations	The Company was incorporated under the laws of the State of Delaware on September 24, 1998. On September 22, 2011, the Company filed a Certificate for Renewal and Revival of Charter with Secretary of State of Delaware. Pursuant to Section 312(1) of the Delaware General Corporation Law, the Company was revived under the new name of “VolitionRx Limited”. The name changed to VolitionRx Limited was approved by FINRA on October 7, 2011 and became effective on October 11, 2011. On October 6, 2011, the Company entered into a share exchange agreement with Singapore Volition Pte. Limited., a Singapore corporation (“Singapore Volition”), and the shareholders of Singapore Volition, which was incorporated on August 5, 2010. Pursuant to the terms of the share exchange agreement, the former shareholders of Singapore Volition held 85% of the issued and outstanding common shares of the Company. The issuance was deemed to be a reverse acquisition for accounting purposes. Singapore Volition, the acquired entity, is regarded as the predecessor entity as of October 6, 2011. The number of shares outstanding and per share amounts has been restated to recognize the recapitalization. The Company’s principal business objective through its subsidiaries is to develop and bring to market simple, easy to use, cost effective blood- tests designed to help diagnose a range of cancers. The tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid – an indication that disease is present. The Company has one wholly-owned subsidiary, Singapore Volition, which it acquired through a share exchange entered into on October 6, 2011. Singapore Volition has two wholly- owned subsidiaries, Belgian Volition SPRL, a Belgium private limited liability company formerly ValiBioSA, (“Belgian Volition”), which it acquired as of September 22, 2010, and Hypergenomics Pte. Limited (“Hypergenomics”), which it formed as of March 7, 2011. Belgian Volition, has two wholly- owned subsidiaries, Volition Diagnostics UK Limited (“Volition Diagnostics”), which it formed as of November 13, 2015 and Volition America, Inc., (“Volition America”), which it formed as of February 3, 2017. Following the acquisition of Singapore Volition, the Company’s fiscal year end was changed from August 31 to December 31.

Going Concern

Going Concern	9 Months Ended
	Sep. 30, 2018
Notes to Financial Statements
Note 2 - Going Concern	Th e Comp ny n n m n p p u n accounting principles generally accepted in the United States of America (“U S GAA pp b go n on wh on mp h o o and qu d o of b in h no m course of bu n Th Comp n has n u losses since inception of $69,435,324 h n g v ow o op on n u n h n v nu wh ub n doub bou b on nu go n on n Th e f u u o h Comp n op n bu n w d p n o b ob u n p on bu on n n n nd o g n v nu m b qu u op on M n g m n p n dd h bov n d b u n dd on g n und b ob n n dd on n n n h oug d b o qu n d v op n n omm n p odu o m n M n g m n on nu x gh o on o on v h Th e a b o h Comp n on nu go n on d p nd n upo b u u accomplish p n d b h p d n p g p n v n u p o b op on Th omp ny n n n m n d no n ud n d u m n h m gh b n h Comp n un b on nu go n on n h Comp n un b ob d qu p ou b o op on

Summary of Significant Accounti

Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2018
Notes to Financial Statements
Note 3 - Summary of Significant Accounting Policies	B asis o P n o The accompanying unaudited condensed consolidated financial statements have been prepared by the Company without audit. In the opinion of management, all adjustments (which include only normal recurring adjustments) necessary to present fairly the financial position, results of operations, and cash flows at September 30, 2018, and for all periods presented herein, have been made. Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted. It is suggested that these unaudited condensed consolidated financial statements be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company's Annual Report on Form 10-K, for the fiscal year ended December 31, 2017, as filed with the Securities and Exchange Commission on March 1, 2018. The results of operations for the periods ended September 30, 2018 and 2017 are not necessarily indicative of the operating results for the full years. The condensed consolidated financial statements of the Company are expressed in United States Dollars. The Company’s fiscal year end is December 31. U se o E m Th e p p o o n n m n on o m w U S GAA qu m n g m n m k m n ump on h h po moun o n b h d o u o on ng n n b h d o h n n m n n h po moun o v nu n xp n du n h po n p od Th Comp n gu v u m n ump on d n om v u o ow n Th e Comp n b m n ump on o u n h o xp n n v ou o h o h b v b on b und h um n h u o wh o h b o m k n udgm n bou h y n v u o n b n h u o o n xp n h no d pp n o o h ou Th u u xp n b h Comp n m d m n dv o h Comp ny m h x n h m d n b w h m n h u u u u u o op on w b d P ri n p o Con o d o Th e acc omp ny n ond n on o d n n m n o h p o nd n ud h oun o h Comp n and on o d on B asic a n D u N Lo P Sh Th e Comp n ompu n o p h o d n w A oun n S nd d Cod o ASC 260 E n ng P Sh wh qu p n o o bo b n d u n ng p h EPS o h o h n om m n B EP ompu b d v d n n o v b ommo h ho d num o b h w gh v g numb o h ou nd n d nom n o du n h p od D u EP g v d u v po n ommo h ou nd n du n h p o u n h u o m ho ompu n d u EPS h v g o p o h p o u d m n n h numb o R eclassificati o Certain amounts presented in previously issued financial statements have been reclassified to be consistent with the current period presentation. In the statement of operations and comprehensive loss, the Company has reclassified the prior year comparative three and nine-month amounts of research and development, sales and marketing and general and administrative to be consistent with the current year classification. R ece n A oun n P onoun m n Management has considered all recent accounting pronouncements issued since the last audit of our consolidated financial statements. The Company’s management believes that these recent pronouncements will not have a material effect on the Company’s consolidated financial statements.

Property and Equipment

Property and Equipment	9 Months Ended
	Sep. 30, 2018
Notes to Financial Statements
Note 4 - Property and Equipment	The Company’s property and equipment consist of the following amounts as of September 30, 2018 and December 31, 2017: September 30, 2018 Accumulated Net Carrying Cost Depreciation Value Useful Life $ $ $ Computer hardware and software 3 years 348,782 151,455 197,327 Laboratory equipment 5 years 1,562,635 863,200 699,435 Office furniture and equipment 5 years 206,014 65,839 140,175 Buildings 30 years 1,522,512 80,342 1,442,170 Building improvements 5-15 years 652,379 67,231 585,148 Land Not amortized 92,885 - 92,885 4,385,207 1,228,067 3,157,140 December 31, 2017 Accumulated Net Carrying Cost Depreciation Value Useful Life $ $ $ Computer hardware and software 3 years 239,133 93,422 145,711 Laboratory equipment 5 years 1,575,354 653,636 921,718 Office furniture and equipment 5 years 207,208 54,479 152,729 Buildings 30 years 1,571,004 43,632 1,527,372 Building improvements 5-15 years 673,157 35,748 637,409 Land Not amortized 95,843 - 95,843 4,361,699 880,917 3,480,782 During the nine-month periods ended September 30, 2018 and September 30, 2017, the Company recognized $406,986 and $306,180, respectively, in depreciation expense.

Intangible Assets

Intangible Assets	9 Months Ended
	Sep. 30, 2018
Notes to Financial Statements
Note 5 - Intangible Assets	The Company’s intangible assets consist of intellectual property and patents, mainly acquired in the acquisition of Belgian Volition. The patents and intellectual property are being amortized over the assets’ estimated useful lives, which range from 8 to 20 years. September 30, 2018 Accumulated Net Carrying Cost Depreciation Value $ $ $ Patents 1,180,956 686,534 494,422 December 31, 2017 Accumulated Net Carrying Cost Depreciation Value $ $ $ Patents 1,213,314 636,917 576,397 During the nine-month periods ended September 30, 2018, and September 30, 2017, the Company recognized $69,584 and $65,182, respectively, in amortization expense. The Company amortizes the long-lived assets on a straight-line basis with terms ranging from 8 to 20 years. The annual estimated amortization schedule over the next five years is as follows: 2018- remaining $ 20,574 2019 $ 90,121 2020 $ 90,121 2021 $ 90,121 2022 $ 90,121 Greater than 5 years $ 113,364 Total Intangible Assets $ 494,422 The Company periodically reviews its long-lived assets to ensure that their carrying value does not exceed their fair market value. The Company carried out such a review in accordance with ASC 360 as of December 31, 2017. The result of this review confirmed that the ongoing value of the patents was not impaired as of December 31, 2017.

Related Party Transactions

Related Party Transactions	9 Months Ended
	Sep. 30, 2018
Notes to Financial Statements
Note 6 - Related Party Transactions	See Note 7 for common stock issued to related parties and Note 8 for stock options and warrants issued to related parties. Th e Comp n h g m n w p o on u n v

Common Stock

Common Stock	9 Months Ended
	Sep. 30, 2018
Notes to Financial Statements
Note 7 - Common Stock	As of September 30, 2018, the Company was authorized to issue 100 million shares of common stock par value $0.001 per share, of which 35,031,225 and 26,519,394 shares were issued outstanding as of September 30, 2018 and December 31, 2017, respectively. On March 13, 2018, the Company issued 3.5 million shares of common stock in a registered public offering at a price of $2.40 per share, for aggregate gross proceeds of $8.4 million. In connection with the transaction, $0.6 million was incurred for legal and underwriting fees resulting in net proceeds of $7.8 million. Pursuant to this offering, the underwriters had the option to purchase up to an additional 525,000 shares of common stock for 30 days following the pricing of the initial closing, which option was not exercised. On August 10, 2018, the Company issued to Cotterford Company Limited in a private placement offering (PIPE) 5 million shares of common stock at a price of $1.80 per share, for aggregate gross proceeds of $9.0 million. Additionally, the Company issued a warrant to purchase up to an additional 5 million shares of common stock at an exercise price of $3.00 per share payable in cash (see Note 8). This transaction resulted in Cotterford Company Limited being a significant shareholder and therefore a related party in accordance with accounting principles. The shares of common stock (including the shares underlying the warrant) were subsequently registered for resale on Form S-3 (declared effective by the SEC on October 15, 2018, File No. 333-227731). On September 7, 2018, the Company entered into an equity distribution agreement with Oppenheimer & Co. Inc.(“Oppenheimer”), which agreement allows it to offer and sell shares of common stock having an aggregate offering price of up to $10.0 million from time to time pursuant to a shelf registration statement on Form S-3 (declared effective by the SEC on September 28, 2018, File No. 333-227248) through Oppenheimer acting as the Company’s agent and/or principal. As of September 30, 2018, the Company had not sold any shares under the equity distribution agreement. On September 7, 2018, an amendment to the 2015 Stock Incentive Plan (the “2015 Plan”) was approved by stockholders at the annual meeting to increase the number of shares of common stock available for issuance under the 2015 Plan by 750,000 shares to an aggregate maximum of 3,250,000 shares. During the nine-month period ended September 30, 2018, 29,375 warrants were exercised to purchase shares of common stock at a price of $2.00 per share in cashless exercises that resulted in the issuance of 11,831 shares of common stock.

Warrants And Options

Warrants And Options	9 Months Ended
	Sep. 30, 2018
Notes to Financial Statements
Note 8 - Warrants and Options	a) Warrants The following table summarizes the changes in warrants outstanding of the Company during the nine-month period ended September 30, 2018: Number of Warrants Weighted Average Exercise Price ($) Outstanding at December 31, 2017 1,731,680 2.36 Granted 5,000,000 3.00 Exercised (29,375 ) 2.00 Expired (24,375 ) 2.98 Outstanding at September 30, 2018 6,677,930 2.84 Exercisable at September 30, 2018 1,552,930 2.35 On August 10, 2018, in conjunction with the PIPE transaction (see Note 7), the Company issued to Cotterford Company Limited a warrant to purchase up to 5.0 million shares of common stock at an exercise price of $3.00 per share payable in cash (subject to adjustment pursuant to the terms of the warrant). The warrant has an expiration date of August 10, 2019 and is exercisable for a period of 6 months commencing on February 10, 2019. Below is a table summarizing the warrants issued and outstanding as of September 30, 2018, which have a weighted average exercise price of $2.84 per share and an aggregate weighted average remaining contractual life of 0.82 years. Weighted Average Remaining Contractual Proceeds to Number Number Exercise Life Company if Outstanding Exercisable Price ($) (Years) Exercised ($) 948,475 948,475 2.20 0.41 2,086,645 520,455 520,455 2.40 0.19 1,249,092 150,000 25,000 2.47 3.93 370,500 5,000,000 - 3.00 0.86 15,000,000 19,000 19,000 3.75 0.13 71,250 40,000 40,000 4.53 2.13 181,200 6,677,930 1,552,930 18,958,687 Warrant expense of $6,453 and $38,806 was recorded in the nine-months ended September 30, 2018 and September 30, 2017, respectively. Total remaining unrecognized compensation cost related to non-vested warrants is approximately $19,137 and is expected to be recognized over a period of 2.3 years. As of September 30, 2018, the total intrinsic value of warrants was $486,792. b) Options The following table summarizes the changes in options outstanding of the Company during the nine-month period ended September 30, 2018: Weighted Average Number of Options Exercise Price ($) Outstanding at December 31, 2017 2,939,134 4.09 Granted 805,000 4.00 Exercised - - Expired/Cancelled (130,167 ) 5.00 Outstanding at September 30, 2018 3,613,967 4.03 Exercisable at September 30, 2018 2,813,967 4.04 Effective January 23, 2018, the Company granted stock options to purchase a total of 780,000 shares of common stock to various Company personnel (including directors, executives, members of management and employees) for services to the Company. These options vest on January 23, 2019 and expire 5 years after the vesting date, with an exercise price of $4.00 per share. The Company has calculated the estimated fair market value of these options at $1,930,265, using the Black-Scholes model and the following assumptions: term 6 years, stock price $3.75, exercise price $4.00, 75.4% volatility, 2.55% risk free rate, and no forfeiture rate. Effective September 28, 2018, the Company granted stock options to purchase 25,000 shares of common stock to the Company controller for services to the Company. These options vest on September 28, 2019 and expire 5 years after the vesting date, with an exercise price of $4.00 per share. The Company has calculated the estimated fair market value of these options at $39,733, using the Black-Scholes model and the following assumptions: term 6 years, stock price $2.59, exercise price $4.00, 77.59% volatility, 3.01% risk free rate, and no forfeiture rate. Below is a table summarizing the options issued and outstanding as of September 30, 2018, all of which were issued pursuant to the 2011 Plan (for option issuances prior to 2016) or the 2015 Plan (for option issuances commencing in 2016) and which have a weighted average exercise price of $4.03 per share and an aggregate weighted average remaining contractual life of 3.36 years. As of September 30, 2018, an aggregate of 789,000 shares of common stock remained available for future issuance under the 2015 Stock Incentive Plan. Weighted Average Remaining Proceeds to Number Number Exercise Contractual Company if Outstanding Exercisable Price ($) Life (Years) Exercised ($) 17,766 17,766 2.35 1.45 41,750 322,500 322,500 2.50 0.39 806,250 322,500 322,500 3.00 1.39 967,500 17,767 17,767 3.35 2.45 59,519 20,000 20,000 3.80 1.13 76,000 1,915,333 1,115,333 4.00 4.60 7,661,332 17,767 17,767 4.35 3.45 77,286 50,000 50,000 4.80 4.26 240,000 930,334 930,334 5.00 3.01 4,651,670 3,613,967 2,813,967 14,581,307 Stock option expense of $1,875,507 and $1,827,604 was recorded in the nine-months ended September 30, 2018 and September 30, 2017, respectively. Total remaining unrecognized compensation cost related to non-vested stock options is approximately $647,899 and is expected to be recognized over a period of 0.99 years. As of September 30, 2018, the total intrinsic value of stock options was $33,289.

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2018
Notes to Financial Statements
Note 9 - Commitments and Contingencies	a) Capital Lease Obligations In 2015, the Company entered into an equipment capital lease to purchase three Tecan machines (automated liquid handling robots) for €550,454 Euros. As of September 30, 2018, the balance payable was $162,357. In 2016, the Company entered into a real estate capital lease with ING Asset Finance Belgium S.A. (“ING”) to purchase a property located in Belgium for €1.12 million Euros. As of September 30, 2018, the balance payable was $719,348. The following is a schedule showing the future minimum lease payments under capital leases by years and the present value of the minimum payments as of September 30, 2018. 2018- remaining $ 39,517 2019 $ 158,066 2020 $ 108,679 2021 $ 62,450 2022 $ 62,449 Greater than 5 years $ 585,445 Total $ 1,016,606 Less: Amount representing interest $ (134,901 ) Present value of minimum lease payments $ 881,705 b) Operating Lease Obligations The Company also leases premises and facilities under operating leases with terms ranging from 12 months to 60 months. As of September 30, 2018, the annual non-cancelable operating lease payments on these leases are as follows: 2018- remaining $ 55,987 2019 $ 65,722 2020 $ 52,864 2021 $ 14,315 Total Operating Lease Obligations $ 188,888 c) Grants Repayable In 2010, the Company entered into an agreement with the Walloon Region government in Belgium for a colorectal cancer research grant for €1.05 million Euros. Per the terms of the agreement, €314,406 Euros of the grant is to be repaid. As of September 30, 2018, the grant balance repayable was $182,758. On July 2, 2018, the Company entered into an agreement with the Walloon Region government in Belgium for a colorectal cancer research grant for €605,000 Euros. Per the terms of the agreement, €181,500 Euros of the grant is to be repaid over 12 years commencing in 2020. As of September 30, 2018, the grant balance repayable was $175,610. As of September 30, 2018, the balance repayable was $358,368 and the annual payments remaining were as follows: 2018- remaining $ -- 2019 $ 40,637 2020 $ 54,685 2021 $ 51,673 2022 $ 48,880 Greater than 5 years $ 162,493 Total Grants Repayable $ 358,368 d) Long-Term Debt In 2016, the Company entered into a 7-year loan agreement with Namur Invest for €440,000 Euros with a fixed interest rate of 4.85%. As of September 30, 2018, the principal balance payable was $430,596. In 2016, the Company entered into a 15-year loan agreement with ING for €270,000 Euros with a fixed interest rate of 2.62%. As of September 30, 2018, the principal balance payable was $283,578. In 2017, the Company entered into a 4-year loan agreement with Namur Invest for €350,000 Euros with a fixed interest rate of 4.00%. As of September 30, 2018, the principal balance payable was $333,282. In 2017, the Company entered into a 7-year loan agreement with SOFINEX for up to €1 million Euros with a fixed interest rate of 4.50%. As of September 30, 2018, €500,000 Euros has been drawn down under this agreement and the principal balance payable was $580,530. On June 27, 2018, the Company entered into a 4-year loan agreement with Namur Innovation and Growth for €500,000 Euros with fixed interest rate of 4.00%. As of September 30, 2018, the principal balance payable was $580,531. As of September 30, 2018, the total balance for long-term debt was $2,208,517 and the payments remaining were as follows: 2018- remaining $ 84,417 2019 $ 491,364 2020 $ 698,181 2021 $ 625,288 2022 $ 271,653 Greater than 5 years $ 323,200 Total $ 2,494,103 Less: Amount representing interest $ (285,586 ) Total Long-Term Debt $ 2,208,517 e) Collaborative Agreement Obligations In 2015, the Company entered into a research sponsorship agreement with DKFZ, in Germany for a 3-year period for €338,984 Euros. As of September 30, 2018, $87,079 is still to be paid by the Company under this agreement. In 2016, the Company entered into a research co-operation agreement with DKFZ, in Germany for a 5-year period for €400,000 Euros. As of September 30, 2018, $232,212 is still to be paid by the Company under this agreement. In 2016, the Company entered into a collaborative research agreement with Munich University, in Germany for a 3-year period for €360,000 Euros. As of September 30, 2018, $246,145 is still to be paid by the Company under this agreement. In 2016, the Company entered into a phase one clinical research agreement with Hvidovre Hospital, University of Copenhagen in Denmark for a 2-year period for DKK 15 million Danish Kroner. As of September 30, 2018, $333,309 is still to be paid by the Company under this agreement. In 2017, the Company entered into a clinical study research agreement with the Regents of the University of Michigan (the “University of Michigan”) for a 3-year period for up to $3 million. As of September 30, 2018, up to $2.0 million is still to be paid by the Company under this agreement. On July 9, 2018, the Company entered into a research collaboration agreement with the University of Taiwan for a 3-year period for a cost to the Company of up to $2.55 million payable over such period. As of September 30, 2018, $2.42 million is still to be paid by the Company under this agreement. As of September 30, 2018, the total amount to be paid for future research and collaboration commitments was $5.32 million and the annual payments remaining were as follows: 2018- remaining $ 1,065,521 2019 $ 2,399,450 2020 $ 963,774 2021 $ 892,500 Total Collaborative Agreement Obligations $ 5,321,245 f) Legal Proceedings There are no legal proceedings which the Company believes will have a material adverse effect on its financial position.

Subsequent Events

Subsequent Events	9 Months Ended
	Sep. 30, 2018
Notes to Financial Statements
Note 10 - Subsequent Events	On October 16, 2018, 60,250 warrants were exercised at a price of $2.20 per share, for net cash proceeds to the Company of $132,550. As a result, a total of 60,250 shares of common stock were issued. On October 16, 2018, 243,903 warrants were exercised at a price of $2.40 per share, for net cash proceeds to the Company of $585,367. As a result, a total of 243,903 shares of common stock were issued.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2018
Summary Of Significant Accounting Policies
Basis of Presentation	The accompanying unaudited condensed consolidated financial statements have been prepared by the Company without audit. In the opinion of management, all adjustments (which include only normal recurring adjustments) necessary to present fairly the financial position, results of operations, and cash flows at September 30, 2018, and for all periods presented herein, have been made. Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted. It is suggested that these unaudited condensed consolidated financial statements be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company's Annual Report on Form 10-K, for the fiscal year ended December 31, 2017, as filed with the Securities and Exchange Commission on March 1, 2018. The results of operations for the periods ended September 30, 2018 and 2017 are not necessarily indicative of the operating results for the full years. The condensed consolidated financial statements of the Company are expressed in United States Dollars. The Company’s fiscal year end is December 31.
Use of Estimates	Th e p p o o n n m n on o m w U S GAA qu m n g m n m k m n ump on h h po moun o n b h d o u o on ng n n b h d o h n n m n n h po moun o v nu n xp n du n h po n p od Th Comp n gu v u m n ump on d n om v u o ow n Th e Comp n b m n ump on o u n h o xp n n v ou o h o h b v b on b und h um n h u o wh o h b o m k n udgm n bou h y n v u o n b n h u o o n xp n h no d pp n o o h ou Th u u xp n b h Comp n m d m n dv o h Comp ny m h x n h m d n b w h m n h u u u u u o op on w b d
Principles of Consolidation	Th e acc omp ny n ond n on o d n n m n o h p o nd n ud h oun o h Comp n and on o d on
Basic and Diluted Net Loss Per Share	Th e Comp n ompu n o p h o d n w A oun n S nd d Cod o ASC 260 E n ng P Sh wh qu p n o o bo b n d u n ng p h EPS o h o h n om m n B EP ompu b d v d n n o v b ommo h ho d num o b h w gh v g numb o h ou nd n d nom n o du n h p od D u EP g v d u v po n ommo h ou nd n du n h p o u n h u o m ho ompu n d u EPS h v g o p o h p o u d m n n h numb o
Reclassification	Certain amounts presented in previously issued financial statements have been reclassified to be consistent with the current period presentation. In the statement of operations and comprehensive loss, the Company has reclassified the prior year comparative three and nine-month amounts of research and development, sales and marketing and general and administrative to be consistent with the current year classification.
Recent Accounting Pronouncements	Management has considered all recent accounting pronouncements issued since the last audit of our consolidated financial statements. The Company’s management believes that these recent pronouncements will not have a material effect on the Company’s consolidated financial statements.

Property and Equipment (Tables)

Property and Equipment (Tables)	9 Months Ended
	Sep. 30, 2018
Property And Equipment Tables
Property and equipment	September 30, 2018 Accumulated Net Carrying Cost Depreciation Value Useful Life $ $ $ Computer hardware and software 3 years 348,782 151,455 197,327 Laboratory equipment 5 years 1,562,635 863,200 699,435 Office furniture and equipment 5 years 206,014 65,839 140,175 Buildings 30 years 1,522,512 80,342 1,442,170 Building improvements 5-15 years 652,379 67,231 585,148 Land Not amortized 92,885 - 92,885 4,385,207 1,228,067 3,157,140 December 31, 2017 Accumulated Net Carrying Cost Depreciation Value Useful Life $ $ $ Computer hardware and software 3 years 239,133 93,422 145,711 Laboratory equipment 5 years 1,575,354 653,636 921,718 Office furniture and equipment 5 years 207,208 54,479 152,729 Buildings 30 years 1,571,004 43,632 1,527,372 Building improvements 5-15 years 673,157 35,748 637,409 Land Not amortized 95,843 - 95,843 4,361,699 880,917 3,480,782

Intangible Assets (Tables)

Intangible Assets (Tables)	9 Months Ended
	Sep. 30, 2018
Intangible Assets Tables
Schedule of intangible assets	September 30, 2018 Accumulated Net Carrying Cost Depreciation Value $ $ $ Patents 1,180,956 686,534 494,422 December 31, 2017 Accumulated Net Carrying Cost Depreciation Value $ $ $ Patents 1,213,314 636,917 576,397
Schedule of intangible assets, future amortization expense	2018- remaining $ 20,574 2019 $ 90,121 2020 $ 90,121 2021 $ 90,121 2022 $ 90,121 Greater than 5 years $ 113,364 Total Intangible Assets $ 494,422

Warrants and Options (Tables)

Warrants and Options (Tables)	9 Months Ended
	Sep. 30, 2018
Warrant [Member]
Summarizes changes in warrants outstanding	Number of Warrants Weighted Average Exercise Price ($) Outstanding at December 31, 2017 1,731,680 2.36 Granted 5,000,000 3.00 Exercised (29,375 ) 2.00 Expired (24,375 ) 2.98 Outstanding at September 30, 2018 6,677,930 2.84 Exercisable at September 30, 2018 1,552,930 2.35
Summarizes warrants issued and outstanding	Weighted Average Remaining Contractual Proceeds to Number Number Exercise Life Company if Outstanding Exercisable Price ($) (Years) Exercised ($) 948,475 948,475 2.20 0.41 2,086,645 520,455 520,455 2.40 0.19 1,249,092 150,000 25,000 2.47 3.93 370,500 5,000,000 - 3.00 0.86 15,000,000 19,000 19,000 3.75 0.13 71,250 40,000 40,000 4.53 2.13 181,200 6,677,930 1,552,930 18,958,687
Option [Member]
Summarizes changes in warrants outstanding	Weighted Average Number of Options Exercise Price ($) Outstanding at December 31, 2017 2,939,134 4.09 Granted 805,000 4.00 Exercised - - Expired/Cancelled (130,167 ) 5.00 Outstanding at September 30, 2018 3,613,967 4.03 Exercisable at September 30, 2018 2,813,967 4.04
Summarizes warrants issued and outstanding	Weighted Average Remaining Proceeds to Number Number Exercise Contractual Company if Outstanding Exercisable Price ($) Life (Years) Exercised ($) 17,766 17,766 2.35 1.45 41,750 322,500 322,500 2.50 0.39 806,250 322,500 322,500 3.00 1.39 967,500 17,767 17,767 3.35 2.45 59,519 20,000 20,000 3.80 1.13 76,000 1,915,333 1,115,333 4.00 4.60 7,661,332 17,767 17,767 4.35 3.45 77,286 50,000 50,000 4.80 4.26 240,000 930,334 930,334 5.00 3.01 4,651,670 3,613,967 2,813,967 14,581,307

Commitments and Contingencies (

Commitments and Contingencies (Tables)	9 Months Ended
	Sep. 30, 2018
Commitments And Contingencies
Schedule of future minimum lease payments for capital leases	2018- remaining $ 39,517 2019 $ 158,066 2020 $ 108,679 2021 $ 62,450 2022 $ 62,449 Greater than 5 years $ 585,445 Total $ 1,016,606 Less: Amount representing interest $ (134,901 ) Present value of minimum lease payments $ 881,705
Operating lease payments	2018- remaining $ 55,987 2019 $ 65,722 2020 $ 52,864 2021 $ 14,315 Total Operating Lease Obligations $ 188,888
Schedule of grants repayable	2018- remaining $ -- 2019 $ 40,637 2020 $ 54,685 2021 $ 51,673 2022 $ 48,880 Greater than 5 years $ 162,493 Total Grants Repayable $ 358,368
Schedule of long term debt	2018- remaining $ 84,417 2019 $ 491,364 2020 $ 698,181 2021 $ 625,288 2022 $ 271,653 Greater than 5 years $ 323,200 Total $ 2,494,103 Less: Amount representing interest $ (285,586 ) Total Long-Term Debt $ 2,208,517
Schedule of collaborative agreement obligations	2018- remaining $ 1,065,521 2019 $ 2,399,450 2020 $ 963,774 2021 $ 892,500 Total Collaborative Agreement Obligations $ 5,321,245

Nature of Operations (Details N

Nature of Operations (Details Narrative)	9 Months Ended
	Sep. 30, 2018
Nature Of Operations
State of incorporation	Delaware
Date of incorporation	Sep. 24, 1998

Going Concern (Details Narrativ

Going Concern (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended		237 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018
Going Concern Details Narrative
Net loss	$ (4,476,649)	$ (3,892,654)	$ (13,721,146)	$ (10,706,325)	$ (69,435,324)

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Details Narrative)	Sep. 30, 2018shares
Dilutive Warrants And Options [Member]
Potentially dilutive warrants and options	10,291,897

Property and Equipment (Details

Property and Equipment (Details) - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2018	Dec. 31, 2017
Cost	$ 4,385,207	$ 4,361,699
Accumulated Depreciation	1,228,067	880,917
Net Carrying Value	$ 3,157,140	$ 3,480,782
Computer hardware and software [Member]
Useful Life	3 years	3 years
Cost	$ 348,782	$ 239,133
Accumulated Depreciation	151,455	93,422
Net Carrying Value	$ 197,327	$ 145,711
Laboratory [Member]
Useful Life	5 years	5 years
Cost	$ 1,562,635	$ 1,575,354
Accumulated Depreciation	863,200	653,636
Net Carrying Value	$ 699,435	$ 921,718
Office Furniture and Equipment [Member]
Useful Life	5 years	5 years
Cost	$ 206,014	$ 207,208
Accumulated Depreciation	65,839	54,479
Net Carrying Value	$ 140,175	$ 152,729
Buildings [Member]
Useful Life	30 years	30 years
Cost	$ 1,522,512	$ 1,571,004
Accumulated Depreciation	80,342	43,632
Net Carrying Value	1,442,170	1,527,372
Building Improvements [Member]
Cost	652,379	673,157
Accumulated Depreciation	67,231	35,748
Net Carrying Value	$ 585,148	$ 637,409
Building Improvements [Member] | Minimum [Member]
Useful Life	5 years	5 years
Building Improvements [Member] | Maximum [Member]
Useful Life	15 years	15 years
Land [Member]
Useful Life	0 years	0 years
Cost	$ 92,885	$ 95,843
Accumulated Depreciation
Net Carrying Value	$ 92,885	$ 95,843

Property and Equipment (Detai_2

Property and Equipment (Details Narrative) - USD ($)	9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017
Property And Equipment Details Narrative
Depreciation Expense	$ 406,986	$ 306,180

Intangible Assets (Details)

Intangible Assets (Details) - USD ($)	Sep. 30, 2018	Dec. 31, 2017
Net Carrying Value	$ 494,422	$ 576,397
Patents [Member]
Cost	1,180,956	1,213,314
Accumulated Amortization	686,534	636,917
Net Carrying Value	$ 494,422	$ 576,397

Intangible Assets (Details 1)

Intangible Assets (Details 1) - USD ($)	Sep. 30, 2018	Dec. 31, 2017
Intangible Assets Details 1
2018- remaining	$ 20,574
2,019	90,121
2,020	90,121
2,021	90,121
2,022	90,121
Thereafter	113,364
Total	$ 494,422	$ 576,397

Intangible Assets (Details Narr

Intangible Assets (Details Narrative) - USD ($)	9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017
Amortization expense	$ 69,584	$ 65,182
Minimum [Member]
Amortization of long-lived asset on straight line basis	8 years
Maximum [Member]
Amortization of long-lived asset on straight line basis	20 years

Common Stock (Details Narrative

Common Stock (Details Narrative) - USD ($)	Sep. 07, 2018	Aug. 10, 2018	Mar. 13, 2018	Sep. 30, 2018	Sep. 30, 2017	Dec. 31, 2017
Option exercised				29,375
Exercise price				$ 2
Common Stock, par value				$ 0.001		$ 0.001
Common Stock, shares authorized				100,000,000		100,000,000
Common Stock, shares issued				35,031,225		26,519,394
Common Stock, shares outstanding				35,031,225		26,519,394
Stock Issued during period, shares				11,831
Proceeds from issuance of common shares				$ 16,796,000	$ 998,412
Stock option [Member]
Option to purchase common stock shares			$ 525,000
Option to purchase common stock shares description			for 30 days following the pricing of the initial closing, which option was not exercised.
Common Stock
Common stock price per share			$ 2.40
Common Stock, shares issued			3,500,000
Legal and underwriting fees			$ 600,000
Net proceeds of legal and underwriting fees			7,800,000
Proceeds from issuance of common shares			$ 8,400,000
Oppenheimer & Co. Inc [Member] | Equity distribution agreement [Member]
Aggregate offering price	$ 10,000,000
Cotterford [Member] | Private Placement [Member]
Exercise price		$ 3
Common stock price per share		$ 1.80
Common Stock, shares issued		5,000,000
Proceeds from issuance of common shares		$ 9,000,000
Warrants issued to purchase common shares		5,000,000
Stock Incentive Plan 2015 [Member] | Minimum [Member]
Common stock shares reserved for future issuance	750,000
Stock Incentive Plan 2015 [Member] | Maximum [Member]
Common stock shares reserved for future issuance	3,250,000

Warrants And Options (Details)

Warrants And Options (Details)	9 Months Ended
	Sep. 30, 2018$ / sharesshares
Number of Warrants
Exercised	29,375
Warrant [Member]
Number of Warrants
Outstanding at December 31, 2017	1,731,680
Granted	5,000,000
Exercised	(29,375)
Expired	(24,375)
Outstanding at September 30, 2018	6,677,930
Exercisable at September 30, 2018	1,552,930
Weighted Average Exercise Price
Outstanding at December 31, 2017 | $ / shares	$ 2.36
Granted | $ / shares	3
Exercised | $ / shares	2
Expired | $ / shares	2.98
Outstanding at September 30, 2018 | $ / shares	2.84
Exercisable at September 30, 2018 | $ / shares	$ 2.35

Warrants And Options (Details 1

Warrants And Options (Details 1)	9 Months Ended
	Sep. 30, 2018USD ($)$ / sharesshares
Warrant One [Member]
Number Outstanding	948,475
Number Exercisable	948,475
Exercise Price | $ / shares	$ 2.2
Weighted Average Remaining Contractual Life (Years)	4 months 28 days
Proceeds to Company if Exercised | $	$ 2,086,645
Warrant Two [Member]
Number Outstanding	520,455
Number Exercisable	520,455
Exercise Price | $ / shares	$ 2.4
Weighted Average Remaining Contractual Life (Years)	2 months 8 days
Proceeds to Company if Exercised | $	$ 1,249,092
Warrant Three [Member]
Number Outstanding	150,000
Number Exercisable	25,000
Exercise Price | $ / shares	$ 2.47
Weighted Average Remaining Contractual Life (Years)	3 years 11 months 4 days
Proceeds to Company if Exercised | $	$ 370,500
Warrant Four [Member]
Number Outstanding	5,000,000
Number Exercisable
Exercise Price | $ / shares	$ 3
Weighted Average Remaining Contractual Life (Years)	10 months 10 days
Proceeds to Company if Exercised | $	$ 15,000,000
Warrant Five [Member]
Number Outstanding	19,000
Number Exercisable	19,000
Exercise Price | $ / shares	$ 3.75
Weighted Average Remaining Contractual Life (Years)	1 month 16 days
Proceeds to Company if Exercised | $	$ 71,250
Warrant Six [Member]
Number Outstanding	40,000
Number Exercisable	40,000
Exercise Price | $ / shares	$ 4.53
Weighted Average Remaining Contractual Life (Years)	2 years 1 month 16 days
Proceeds to Company if Exercised | $	$ 181,200
Warrant [Member]
Number Outstanding	6,677,930
Number Exercisable	1,552,930
Proceeds to Company if Exercised | $	$ 18,958,687

Warrants And Options (Details 2

Warrants And Options (Details 2)	9 Months Ended
	Sep. 30, 2018$ / sharesshares
Number of Options
Exercised	29,375
Option [Member]
Number of Options
Outstanding at December 31, 2017	2,939,134
Granted	805,000
Exercised
Expired/Cancelled	(130,167)
Outstanding at September 30, 2018	3,613,967
Exercisable at September 30, 2018	2,813,967
Weighted Average Exercise Price
Outstanding at December 31, 2017 | $ / shares	$ 4.09
Granted | $ / shares	4
Exercised | $ / shares
Expired/Cancelled | $ / shares	5
Outstanding at September 30, 2018 | $ / shares	4.03
Exercisable at September 30, 2018 | $ / shares	$ 4.04

Warrants And Options (Details 3

Warrants And Options (Details 3)	9 Months Ended
	Sep. 30, 2018USD ($)$ / sharesshares
Option One [Member]
Number Outstanding	17,766
Number Exercisable	17,766
Exercise Price | $ / shares	$ 2.35
Weighted Average Remaining Contractual Life (Years)	1 year 5 months 12 days
Proceeds to Company if Exercised | $	$ 41,750
Option Two [Member]
Number Outstanding	322,500
Number Exercisable	322,500
Exercise Price | $ / shares	$ 2.5
Weighted Average Remaining Contractual Life (Years)	4 months 20 days
Proceeds to Company if Exercised | $	$ 806,250
Option Three [Member]
Number Outstanding	322,500
Number Exercisable	322,500
Exercise Price | $ / shares	$ 3
Weighted Average Remaining Contractual Life (Years)	2 years 5 months 12 days
Proceeds to Company if Exercised | $	$ 967,500
Option Four [Member]
Number Outstanding	17,767
Number Exercisable	17,767
Exercise Price | $ / shares	$ 3.35
Weighted Average Remaining Contractual Life (Years)	2 years 5 months 12 days
Proceeds to Company if Exercised | $	$ 59,519
Option Five [Member]
Number Outstanding	20,000
Number Exercisable	20,000
Exercise Price | $ / shares	$ 3.8
Weighted Average Remaining Contractual Life (Years)	1 year 1 month 16 days
Proceeds to Company if Exercised | $	$ 76,000
Option Six [Member]
Number Outstanding	1,915,333
Number Exercisable	1,115,333
Exercise Price | $ / shares	$ 4
Weighted Average Remaining Contractual Life (Years)	4 years 7 months 6 days
Proceeds to Company if Exercised | $	$ 7,661,332
Option Seven [Member]
Number Outstanding	17,767
Number Exercisable	17,767
Exercise Price | $ / shares	$ 4.35
Weighted Average Remaining Contractual Life (Years)	3 years 5 months 12 days
Proceeds to Company if Exercised | $	$ 77,286
Option Eight [Member]
Number Outstanding	50,000
Number Exercisable	50,000
Exercise Price | $ / shares	$ 4.8
Weighted Average Remaining Contractual Life (Years)	4 years 3 months 4 days
Proceeds to Company if Exercised | $	$ 240,000
Option Nine [Member]
Number Outstanding	930,334
Number Exercisable	930,334
Exercise Price | $ / shares	$ 5
Weighted Average Remaining Contractual Life (Years)	3 years 4 days
Proceeds to Company if Exercised | $	$ 4,651,670
Option [Member]
Number Outstanding	3,613,967
Number Exercisable	2,813,967
Proceeds to Company if Exercised | $	$ 14,581,307

Warrants And Options (Details N

Warrants And Options (Details Narrative) - USD ($)	Aug. 10, 2018	Sep. 28, 2018	Sep. 30, 2018	Sep. 30, 2017	Dec. 31, 2017
Unrecognized compensation cost of non-vested stock options			$ 647,899
Unrecognized compensation cost of non-vested warrants recognition period			6 months 25 days
Stock based compensation			$ 1,875,507	$ 1,827,604
Private Placement [Member] | Cotterford [Member]
Warrants issued to purchase common shares	5,000,000
Exercise price	$ 3
Expiration date	Aug. 10, 2019
Warrant [Member]
Outstanding at September 30, 2018			$ 2.84		$ 2.36
Weighted average remaining contractual life			9 months 25 days
Unrecognized compensation cost of non-vested stock options			$ 19,137
Unrecognized compensation cost of non-vested warrants recognition period			2 years 3 months 19 days
Aggregate Intrinsic value			$ 486,792
Warrant expense			$ 6,453	$ 38,806
Stock option [Member] | 2011 Plan Or 2015 [Member]
Weighted average remaining contractual life			3 years 4 months 9 days
Weighted average exercise price			$ 4.03
Common stock shares reserved for future issuance			789,000
Stock option [Member] | On January 23, 2018 [Member]
Common stock purchase			780,000
Exercise price			$ 4
Stock per share price			$ 3.75
Expected term			6 years
Volatility			75.40%
Risk free rate			2.55%
Stock option vesting date			Jan. 23, 2019
Term			5 years
Fair market value			$ 1,930,265
Stock option [Member]
Common stock purchase		25,000
Exercise price		$ 4
Stock per share price		$ 2.59
Expected term		6 years
Volatility		77.59%
Risk free rate		3.01%
Stock option vesting date		Sep. 28, 2019
Term		5 years
Fair market value		$ 39,733
Aggregate Intrinsic value			$ 33,289

Commitments and Contingencies_2

Commitments and Contingencies (Details)	Sep. 30, 2018USD ($)
Commitments And Contingencies Details
2018- remaining	$ 39,517
2,019	158,066
2,020	108,679
2,021	62,450
2,022	62,449
Greater than 5 years	585,445
Total	1,016,606
Less: Amount representing interest	(134,901)
Present value of minimum lease payments	$ 881,705

Commitments and Contingencies_3

Commitments and Contingencies (Details 1)	Sep. 30, 2018USD ($)
Disclosure Commitments And Contingencies Details 1Abstract
2018- remaining	$ 55,987
2,019	65,722
2,020	52,864
2,021	14,315
Total Operating Lease Obligations	$ 188,888

Commitments and Contingencies_4

Commitments and Contingencies (Details 2)	Sep. 30, 2018USD ($)
Disclosure Commitments And Contingencies Details 2Abstract
2018- remaining
2,019	40,637
2,020	54,685
2,021	51,673
2,022	48,880
Greater than 5 years	162,493
Total Grants Repayable	$ 358,368

Commitments and Contingencies_5

Commitments and Contingencies (Details 3)	Sep. 30, 2018USD ($)
Disclosure Commitments And Contingencies Details 3Abstract
2018- remaining	$ 84,417
2,019	491,364
2,020	698,181
2,021	625,288
2,022	271,653
Greater than 5 years	323,200
Total	2,494,103
Less: Amount representing interest	(285,586)
Total Long-Term Debt	$ 2,208,517

Commitments and Contingencies_6

Commitments and Contingencies (Details 4)	Sep. 30, 2018USD ($)
Disclosure Commitments And Contingencies Details 4Abstract
2018- remaining	$ 1,065,521
2,019	2,399,450
2,020	963,774
2,021	892,500
Total Collaborative Agreement Obligations	$ 5,321,245

Commitments and Contingencies_7

Commitments and Contingencies (Details Narrative)	Jul. 09, 2018	Jul. 02, 2018USD ($)	Jun. 27, 2018USD ($)	Jun. 27, 2018EUR (€)	Sep. 30, 2018USD ($)	Sep. 30, 2018EUR (€)	Sep. 30, 2018EUR (€)	Jul. 02, 2018EUR (€)
Total long-term debt payable					$ 2,208,517
Total Grants Repayable					358,368
Total Collaborative Agreement Obligations					$ 5,321,245
Maximum [Member]
Lease agreement expire period					60 months	60 months
Minimum [Member]
Lease agreement expire period					12 months	12 months
University of Taiwan [Member] | Clinical Study Research Agreement [Member]
Lease agreement expire period	3 years
Collaborative obligations amount					$ 2,550,000
Collaborative obligations amount due					$ 2,420,000
Walloon Region Government [Member] | Colorectal Cancer Research Agreement [Member]
Amount payable		$ 175,610
Grant receivable | €								€ 605,000
Repayment of grants | €								€ 181,500
Terms of agreement description		<font style="font: 10pt Times New Roman, Times, Serif">The grant is to be repaid over 12 years commencing in 2020.</font></p>" id="sjs-C17">&lt;p style="text-align: justify">&lt;font style="font: 10pt Times New Roman, Times, Serif">The grant is to be repaid over 12 years commencing in 2020.&lt;/font>&lt;/p>
In 2017 [Member] | University of Michigan [Member] | Clinical Study Research Agreement [Member]
Lease agreement expire period					3 years	3 years
Collaborative obligations amount					$ 3,000,000
Collaborative obligations amount due					2,000,000
In 2016 [Member] | Capital Lease Obligations [Member] | ING Asset Finance Belgium S.A. [Member]
Purchase price for the property | €							€ 1,120,000
Amount payable					$ 719,348
In 2016 [Member] | Hvidovre Hospital [Member] | Clinical Research Agreement [Member]
Lease agreement expire period					2 years	2 years
Collaborative obligations amount | €							15,000,000
Collaborative obligations amount due					$ 333,309
In 2016 [Member] | Munich University [Member] | Collaborative Research Agreement [Member]
Lease agreement expire period					3 years	3 years
Collaborative obligations amount | €							360,000
Collaborative obligations amount due					$ 246,145
In 2016 [Member] | DKFZ [Member] | Research Co-operation Agreement [Member]
Lease agreement expire period					5 years	5 years
Collaborative obligations amount | €							400,000
Collaborative obligations amount due					$ 232,212
In 2015 [Member] | Capital Lease Obligations [Member] | Automated Liquid Handling Robots [Member]
Purchase price for the property | €							550,454
Amount payable					$ 162,357
In 2015 [Member] | DKFZ [Member] | Research Sponsorship Agreement [Member]
Lease agreement expire period					3 years	3 years
Collaborative obligations amount | €							€ 338,984
Collaborative obligations amount due					$ 87,079
In 2010 [Member] | Walloon Region Government [Member]
Amount payable					182,758
Grant receivable					1,050,000
Repayment of grants					$ 314,406
Long-term Debt [Member] | In 2017 [Member] | Namur Invest [Member]
Loan agreement term					4 years	4 years
Fixed interest rate on lease			4.00%	4.00%
Lease payment | €						€ 350,000
Principal balance payable on lease					$ 333,282
Long-term Debt [Member] | In 2017 [Member] | SOFINEX [Member]
Loan agreement term					7 years	7 years
Fixed interest rate on lease					4.50%		4.50%
Lease payment | €						€ 1,000,000
Principal balance payable on lease					$ 580,530
Under agreement cash Withdrawn | €							€ 500,000
Long-term Debt [Member] | In 2016 [Member] | Namur Invest [Member]
Loan agreement term					7 years	7 years
Fixed interest rate on lease					4.85%		4.85%
Lease payment | €						€ 440,000
Principal balance payable on lease					$ 430,596
Long-term Debt [Member] | In 2016 [Member] | ING [Member]
Loan agreement term					15 years	15 years
Fixed interest rate on lease					2.62%		2.62%
Lease payment | €						€ 270,000
Principal balance payable on lease					$ 283,578
Long-term Debt [Member] | Namur Innovation and Growth [Member] | In 2017 [Member]
Loan agreement term			4 years	4 years
Fixed interest rate on lease					4.00%		4.00%
Lease payment | €				€ 500,000
Principal balance payable on lease			$ 580,531

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - USD ($)	1 Months Ended
	Oct. 16, 2018	Sep. 30, 2018
Warrants exercise price per share		$ 2
Subsequent Event [Member] | Warrant [Member] | Exercise One [Member]
Common stock shares issued upon exercise of rights	60,250
Warrants exercise price per share	$ 2.20
Proceeds from warrant exercises	$ 132,550
Subsequent Event [Member] | Warrant [Member] | Exercise Two [Member]
Common stock shares issued upon exercise of rights	243,903
Warrants exercise price per share	$ 2.40
Proceeds from warrant exercises	$ 585,367